Search

• Ceftriaxone can cause encephalopathy in patients with end-stage renal disease. • Ceftriaxone-associated encephalopathy (CAE) can develop even at a dose of 1 g/day. • A high blood and cerebrospinal fluid ceftriaxone level may be CAE-related. • Estimation of ceftriaxone level may contribute to an accurate diagnosis. Neurotoxicity is a rare and intolerable adverse effect of ceftriaxone therapy. In most cases, it has been diagnosed on the basis of medical history rather than quantitative blood and cerebrospinal fluid testing. We report the case of a woman aged 78 years with ceftriaxone-associated encephalopathy. She regularly underwent hemodialysis. The patient received intravenous ceftriaxone at a dose of 1 g/day for 10 days for a urinary tract infection, and her consciousness level began to deteriorate during the therapy. Five days after ceftriaxone discontinuation, her symptoms rapidly improved. Thus, ceftriaxone-associated encephalopathy was suspected. Ceftriaxone levels in the blood and cerebrospinal fluid were high while the patient had disturbed consciousness. This case showed that ceftriaxone levels were related to ceftriaxone-associated encephalopathy. Therefore, the estimation of ceftriaxone levels may facilitate an accurate diagnosis. [ABSTRACT FROM AUTHOR]

Neurotoxicity is a rare and intolerable adverse effect associated with levofloxacin therapy, whose diagnosis has mostly been reported based on medical history rather than quantitative measures in the blood. We report a 68-year-old man with levofloxacin-associated encephalopathy and myoclonus with high levels of levofloxacin in the blood and cerebrospinal fluid. After hemodialysis, these decreased, and his symptoms rapidly improved. An electroencephalogram was also normal. This case showed the concentration of levofloxacin to be clearly related to levofloxacin-associated neurotoxicity. Therefore, an estimation of its concentration may contribute to accurate diagnosis. [ABSTRACT FROM AUTHOR]

• Adenosine deaminase (ADA) in the cerebrospinal fluid (CSF) is not specific for diagnosing tuberculous meningitis in HIV infected patients. • Retroviral rebound syndrome can cause meningitis and can also cause ADA elevation in the CSF. • We have to be aware of retroviral rebound syndrome as a cause of ADA elevation in CSF, to avoid unnecessary anti-tuberculous treatment. Adenosine deaminase (ADA) in cerebrospinal fluid (CSF) is considered to be a useful biomarker in differentiating tuberculous meningitis (TBM) from other meningitis in non-HIV patients. However, its specificity decreases in patients with HIV, and other diseases such as cytomegalovirus encephalitis, toxoplasmosis or meningeal lymphomatosis can also elevate ADA in CSF. We here report a rare case of retroviral rebound syndrome in a HIV patient, whose ADA in CSF was elevated. [ABSTRACT FROM AUTHOR]